Methods for the prevention of aggregation of viral components
AssigneeDe Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en Sport
InventorsArend Gesinus van't Oever, Wilfridus Adrianus Maria Bakker, Yvonne Elisabeth Thomassen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for prevention and/or reduction of aggregation of viral components.
Claims14
A method for producing a composition comprising Enteroviral particles, the method comprising, sequentially:
- (a) purifying Enteroviral particles from a medium containing Enteroviral particles, whereby during at least a part of the purification a basic amino acid or a derivative thereof is present at a concentration between 0.5-1000 mM to prevent or reduce aggregation of the Enteroviral particles;
- and, optionally, at least one of:
- (b) inactivating the Enteroviral particles;
- and,
- (c) formulating the Enteroviral particles,
- wherein the basic amino acid or derivative thereof is selected from the group consisting of arginine, lysine, histidine, arginine-HCl , lysine-HCl , histidine-HCl , agmatine, L-arginine ethyl ester dihydrochloride, tranexamic acid, DL-5-hydroxylysine hydrochloride, L-lysine methyl ester dihydrochloride, 3-methyl-L-histidine, salts thereof and combinations thereof.
A method of preventing or reducing aggregation of Enteroviral particles during purification of the Enteroviral particles from a medium, the method comprising adding to a composition comprising Enteroviral particles a basic amino acid or derivative thereof selected from the group consisting of arginine, lysine, histidine, arginine-HCl , lysine-HCl , histidine-HCl , agmatine, L-arginine ethyl ester dihydrochloride, tranexamic acid, DL-5-hydroxylysine hydrochloride, L-lysine methyl ester dihydrochloride, 3-methyl-L-histidine, salts thereof and combinations thereof,
- wherein during at least a part of the purification the basic amino acid or a derivative thereof is present at a concentration between 0.5-1000 mM to prevent or reduce aggregation of the viral component.
Dependencies are inferred from the claim text.